Summer 2026
Posted on 5/16/2026
Develops subcutaneous insulin pumps and software
$30 - $41/hr
No H1B Sponsorship
San Diego, CA, USA
Hybrid
Hybrid role; on-site required in San Diego, CA.
See people who can refer or advise you
Tandem Diabetes Care designs and sells insulin pumps and related software for people with diabetes. Its flagship product is the t:slim X2 insulin pump, a subcutaneous device that delivers insulin and can work with other diabetes management devices through interoperable technology. A key feature is Basal-IQ, which uses continuous glucose monitoring data to predict low blood sugar and pause insulin delivery to prevent hypoglycemia. The company generates revenue from selling pumps and accessories like infusion sets and cartridges, as well as software updates and subscriptions for advanced management features, creating recurring income. Tandem differentiates itself with interoperable hardware and software that aim to simplify diabetes care and integrate with other devices, not just sell a single pump. Its goal is to improve diabetes management and quality of life by providing user-friendly, connected insulin delivery and management solutions for patients aged six and older.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
2006
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Holidays
401(k) Company Match
Remote Work Options
Hybrid Work Options
Employee Stock Purchase Plan
Performance Bonus
Tandem Diabetes Care met Wall Street's revenue expectations in Q2 2026, reporting sales of $254.6 million, up 5.8% year on year. The diabetes technology company's GAAP loss of $0.31 per share aligned with analyst estimates. The company reaffirmed its full-year revenue guidance of $1.08 billion at the midpoint, close to analyst forecasts. Adjusted EBITDA of $6.42 million beat expectations by 82.2%, with a 2.5% margin. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. However, free cash flow was -$38.67 million, compared to -$15.7 million in Q2 2025. Analysts expect revenue to grow 9.3% over the next 12 months. Over the past five years, Tandem Diabetes has grown sales at an 11.5% compounded annual growth rate.
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) given consensus rating of "Hold" by analysts. July 30, 2026 Key points. * Analysts rate Tandem Diabetes Care "Hold" overall: Of 22 firms, 11 recommend holding, nine recommend buying, one strongly recommends buying, and one recommends selling. The average 12-month price target is $28.73. * Recent analyst actions were mixed, with TD Cowen raising its target to $28 while Bank of America and Citigroup cut targets to $25 and $17, respectively. * Tandem reported better-than-expected quarterly results, including an adjusted loss of $0.30 per share versus the $0.46 expected and revenue of $247.2 million, up 5.5% year over year. Shares opened at $18.59, while several institutional investors recently established or expanded positions. * Interested in Tandem Diabetes Care? Here are five stocks we like better. Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-two research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $28.7250. TNDM has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Tandem Diabetes Care in a research note on Tuesday, June 23rd. They issued a "hold" rating and a $15.50 target price for the company. TD Cowen restated a "buy" rating and set a $28.00 price target (up from $25.00) on shares of Tandem Diabetes Care in a research note on Monday, April 20th. Bank of America decreased their price target on shares of Tandem Diabetes Care from $35.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, May 18th. Benchmark assumed coverage on shares of Tandem Diabetes Care in a research note on Monday, May 11th. They set a "hold" rating for the company. Finally, Citigroup reissued a "neutral" rating and set a $17.00 price objective (down from $22.00) on shares of Tandem Diabetes Care in a report on Thursday, May 28th. Institutional trading of Tandem Diabetes Care. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Freestone Grove Partners LP acquired a new position in shares of Tandem Diabetes Care in the third quarter valued at about $22,706,000. First Light Asset Management LLC purchased a new position in shares of Tandem Diabetes Care in the fourth quarter worth about $23,947,000. BNP Paribas Financial Markets lifted its holdings in shares of Tandem Diabetes Care by 468.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company's stock worth $27,442,000 after purchasing an additional 1,028,866 shares during the period. Marshall Wace LLP acquired a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $19,244,000. Finally, Defilade Capital Management L.P. purchased a new stake in Tandem Diabetes Care in the first quarter valued at approximately $14,606,000. Tandem Diabetes Care trading up 4.7%. Tandem Diabetes Care stock opened at $18.59 on Thursday. The stock has a 50-day moving average of $16.36 and a two-hundred day moving average of $18.92. The company has a debt-to-equity ratio of 4.54, a quick ratio of 3.07 and a current ratio of 3.58. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $29.65. The stock has a market cap of $1.27 billion, a PE ratio of -13.28 and a beta of 1.58. Discover more Cryptocurrency News investment Stock Screener Tool Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The business had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. The company's revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Tandem Diabetes Care will post -0.72 EPS for the current fiscal year. About Tandem Diabetes Care. Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim(R) Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities. The company's flagship offering, the t:slim X2(R) Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Tandem Diabetes Care, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list. While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Tandem Diabetes reported Q1 revenues of $247.2 million, up 5.5% year on year and beating analysts' expectations by 3.2%. The company also beat earnings per share estimates, whilst full-year revenue guidance met analyst expectations. Despite the strong quarter, the stock has fallen 16.1% since reporting and now trades at $15.50. Investor expectations may have been higher than Wall Street's published projections. The healthcare technology sector overall reported a strong Q1, with the seven stocks tracked beating revenue consensus estimates by 1.6%. Next quarter's revenue guidance came in 2.8% above expectations. Healthcare technology shares have risen 21.9% on average since the latest earnings results. The sector benefits from healthcare digitalisation, regulatory incentives, and labour shortages driving automation demand. However, it faces challenges including lengthy sales cycles, complex regulatory requirements, and integration difficulties with legacy systems.
Top diabetes tech stories from the first half of 2026. Multi-analyte sensors, insulin patch pumps and regulatory actions have led diabetes tech news in 2026. Here are some highlights of MedTech Dive's coverage. Published July 7, 2026 It's been a busy year for the diabetes technology space, with companies unveiling new technologies, developing products to match their rivals and grappling with regulatory actions that have highlighted quality concerns. At the beginning of the year, the Food and Drug Administration issued a string of warning letters to Abbott, Beta Bionics and Unomedical over quality issues with continuous glucose monitors and insulin pumps. Dexcom disclosed some CGMs it had discarded were stolen and being resold. Companies also announced plans for new diabetes devices and aspirations for expanded insurance coverage. Abbott received a CE mark for a dual glucose-ketone sensor, intended to help people with diabetes avoid a serious complication called diabetic ketoacidosis. Multiple insulin pump makers, including Insulet and MiniMed, discussed plans to design fully closed loop automated insulin delivery systems, which would allow people to manage their diabetes without meal announcements or bolus insulin doses. Meanwhile, Tandem Diabetes Care and Beta Bionics announced timelines for tubeless insulin pumps, which would position them to compete with market leader Insulet. Here are the top stories from the first half of the year. * 4 diabetes tech execs on the future of multi-analyte glucose sensors By Elise Reuter - June 22, 2026 Executives with Abbott, PercuSense and Biolinq spoke with MedTech Dive about what's next with multi-analyte sensor technology. Read the full article | * Diabetes tech companies are racing toward 'fully closed loop' devices. But automation comes with trade-offs. By Elise Reuter - June 4, 2026 Insulet, MiniMed and Tandem Diabetes Care are all working on systems to take meal announcements out of diabetes management. Read the full article | * Abbott receives CE mark for dual glucose-ketone sensor By Elise Reuter - May 27, 2026 Abbott's first dual-analyte sensor comes as competitors are working to develop their own versions of the technology. Read the full article | * Insulet recalls 7M patch pumps due to leak risk By Elise Reuter - May 27, 2026 The recall is Insulet's second this year related to tears in the device tubing. So far, 24 serious adverse events have been reported. Read the full article | * Beta Bionics to launch its first insulin patch pump to compete with Insulet By Elise Reuter - May 26, 2026 The device called Mint, which would work with the company's adaptive insulin dosing algorithm, is expected to debut in the first half of 2027. Read the full article | * Dexcom warns of scrapped glucose sensors being resold By Elise Reuter - May 26, 2026 Dexcom has identified two lots of G7 sensors that have been stolen, sold and used by customers. Read the full article | * Tandem to file tubeless insulin pump with FDA this quarter By Elise Reuter - May 8, 2026 The new version of Tandem's Mobi pump would be the diabetes technology company's first tubeless device. Read the full article | * MiniMed gets FDA nod for smaller insulin pump By Elise Reuter - March 18, 2026 MiniMed Flex is a smartphone-controlled insulin pump about half the size of MiniMed's previous device. It's the company's first launch since separating from Medtronic in early March. Read the full article | * Medtronic's MiniMed goes public for $560M By Elise Reuter - March 6, 2026 The diabetes tech business is now operating as a standalone, public company. Shares began trading on Friday. Read the full article | * FDA warns insulin infusion set maker Unomedical over leaks, mishandled complaints By Elise Reuter - March 2, 2026 Unomedical, which supplies diabetes tech firms including Medtronic, Tandem Diabetes Care and Beta Bionics, received more than 5,000 complaints about leaking infusion sets between 2023 and 2025. Read the full article | * FDA warns Beta Bionics on unreported complaints, insulin pump changes By Elise Reuter - Feb. 26, 2026 The Food and Drug Administration warning letter detailed unreported low blood sugar and a software change to correct for delayed glucose readings. Read the full article | * Abbott receives FDA warning letter over Freestyle Libre CGMs By Elise Reuter - Feb. 3, 2026 Abbott needs to conduct more performance testing to ensure its FreeStyle Libre devices are accurate, FDA inspectors found. Read the full article Filed Under: FDA
Tandem Diabetes Care reported first-quarter revenue of $247.2 million, up 5.5% year over year, whilst shipping over 19,000 pumps in the US and 10,000 internationally. Gross margin expanded 482 basis points to 55.3%, and operating cash flow turned positive at $11.1 million versus a $21.2 million outflow last year. The company is shifting more US business towards a pharmacy-based, pay-as-you-go model, which can reduce near-term sales but lowers barriers for new pump users. Pharmacy sales represented 6% of US sales in Q1. Tandem's pump portfolio centres on Tandem Mobi and t:slim X2, both powered by Control-IQ closed-loop technology. The t:slim X2 offers remote feature updates, allowing users to stay current without full hardware replacement. Despite progress, TNDM shares fell 10.9% in Q1.